Quarterly Report • May 4, 2017
Quarterly Report
Open in ViewerOpens in native device viewer
Corporate registration number 556822-1187
First quarter (January-March 2017)
Key events during the first quarter
Key events after the end of the first quarter
| Key figures1 | Jan-Mar | Jan-Mar | Full year |
|---|---|---|---|
| 2017 | 2016 | 2016 | |
| Revenues2 , SEKm |
41,0 | 26,0 | 128,3 |
| EBITDA3 , SEKm |
13,4 | -1,6 | 15,1 |
| EBITDA margin3 , % |
33% | -6% | 12% |
| Operating profit, SEKm | 4,4 | -9,9 | -18,3 |
| Net profit/loss for the period2 , SEKm |
4,1 | -11,2 | -26,9 |
| Operating cash flow, SEKm | -2,0 | 1,8 | -19,8 |
| Earnings per share2 , SEK |
0,12 | -0,34 | -0,81 |
| Operating cash flow per share, SEK | -0,06 | 0,05 | -0,60 |
| Equity ratio, % | 61% | 61% | 62% |
| Net debt3 , SEKm |
151,3 | 117,4 | 134,4 |
| Number of shares at the end of period | 33 302 373 | 33 302 373 | 33 302 373 |
| Weighted average number of shares2 | 33 302 373 | 33 302 373 | 33 302 373 |
1Definition of key figures are presented on page 15
2Defined according to IFRS
3Reconciliation of key figure see page 15
Our focus for 2017, to continue our hard work on both the revenue and cost side, which I outlined in the year-end report for 2016, is beginning to have effect and we are closing in on our long term financial targets. During the first quarter, we reached the target of an EBITDA-margin of 30 percent. We also reached the target of increasing sales by 20 percent, even excluding the revenue generated by a new licensing deal.
The reason for the improved results, besides the new licensing deal, is that we have higher revenues from C.R. Bard and continued cost control. The volume of products sold from our own portfolio is lower than last year, but the product mix makes the value almost in line with the previous year. This means that we are selling more central venous catheters (CVCs) and the new generation of endotracheal tubes (ETTs), which generate higher revenue per product than the Foley catheters. At the beginning of 2017 we communicated that we will focus more on revenue development than on volume. The goal of doubling sales generated by our own portfolio of products this year remains.
The first quarter's main event was the licensing deal with Smartwise Sweden AB, which was announced in February. The deal with Smartwise opens up a whole new area of application for our technology. Through advanced injection systems drugs and other therapies can be targeted and delivered to damaged tissue in vital organs, for example following a stroke or heart attack. Thereby, high doses of chemotherapy can for example be injected into cancer tumours, without negative systemic side effects. During 2017, Smartwise will pay a total of USD 2.5 million for the exclusive and global rights to this application area and, when the products reach the market, Bactiguard will receive royalty income. The first payment of 1 million USD was recognized as revenue in the first quarter and generated cash flow in April. The remaining payments will be evenly distributed over the year.
The cooperation with C.R. Bard is stable and will not been adversely affected by Becton Dickinson's recently announced acquisition. Growth within the area of infection prevention is highlighted as one of four strategic reasons for the acquisition, where the prevention of surgical site infections and catheter related blood and urinary tract infections are in focus. These infections are the most common and lead to major costs for the healthcare system. C.R. Bard is the market leader in the US and Japan with Foley catheters for infection control, using the Bactiguard coating. In parallel with developing our current licensing business, we have a high level of activity in developing new.
Marketwise, the first quarter was primarily characterized by the entry into one of the major European markets. The partnership with Roeser in Germany is going well and during the first quarter a second delivery of products was made, following the one that was delivered at the end of 2016. To support the rollout in Germany and the entry into other major European markets, we have hired a Sales Director for Europe. We now have a solid base in Europe and the right staff to develop our presence in more of the large European markets.
In Sweden, we continue to make progress and in April, after the end of the quarter, we won yet another tender in Kalmar. Kalmar County Council has been using our products during the past two years and decided to continue using infection prevention catheters by specifically demanding this in their latest tender. We are also focusing a lot on education and in March we presented, for the first time, our self-developed tool BIP CIP to a large group of healthcare professionals. At our headquarters, we conducted professional education for nurses working in elderly care, with the aim of reducing infections associated with catheter treatment.
In our two largest markets, China and India, the intensive work continued during the quarter. In China with continued focus on training initiatives and sales activities aimed at hospitals and in India by focusing on expanding the current distributor network with more regional distributors. We are confident about the continued development on both these markets in 2017.
In the Middle East, a region which did not live up to our expectations in 2016, our investments in marketing and sales resources have started to pay off. In January, we signed a distributor agreement for Egypt which is the most populous country in the Middle East and Northern Africa. The product registration process is well under way and a first order and launch is to be expected during the second quarter of this year.
Finally, I am also pleased to note that we further strengthen our clinical evidence through the independent clinical study from Hong Kong, which was published in February. It confirms once again that Bactiguard coated Foley catheters reduce the number of symptomatic catheter related urinary tract infections and that the effect is even more pronounced for long-term users.
Christian Kinch
CEO
Bactiguard signs distribution agreement and enters partnership with Heal Pharma for Egypt. The product registration has been initiated and market launch is planned for the second quarter of 2017.
Egypt is the most populous country in North Africa and the Middle East, with a population of approximately 90 million. Heal Pharma, based in Cairo, has a nationwide reach and was established in 2008 by Dr Mohamed Khalifa.
Bactiguard and Smartwise Sweden AB (Smartwise) have entered into a joint development project for advanced, Bactiguard-coated vascular injection catheters. At the same time, a license agreement has been signed. Smartwise will pay USD 2.5 million in 2017, for the exclusive and global right to the Bactiguard technology for this application, and followed by royalty payments once the products are commercialized.
By entering the agreement with Smartwise, Bactiguard expands its license business to comprise three different therapeutic areas, Foley catheters, orthopaedic implants and now, advanced transvascular injection catheters. Smartwise is owned by a group of private investors, including Christian Kinch and Thomas von Koch.
A recent, independent clinical study conducted in Hong Kong confirms that Bactiguard-coated Foley catheters reduce symptomatic catheter associated urinary tract infections and that the effect is even more pronounced among long-term users.
This is the first study conducted in a Chinese population and included 306 patients from a rehabilitation hospital in Hong Kong. The incidence of catheter associated urinary tract infections was 31 % lower for patients with Bactiguard-coated Foley catheters (BIP Foley) compared to patients with standard latex Foley catheters (P=0.095). A subgroup analysis showed a 48% lower infection rate among long-term users (~60 days with catheter) with Bactiguard coated catheters compared to standard catheters (P=0.027).
The study is published in the Hong Kong Medical Journal.
(Chung et al. A prospective interventional study to examine the effect of a silver alloy and hydrogel−coated catheter on the incidence of catheter-associated urinary tract infection. HK Medical Journal 2017)
Bactiguard has won a tender for urinary catheters covering the Swedish county Kalmar. The contract is an extension of the previous agreement, lasts for 4 years and enables healthcare providers to purchase Bactiguards' anti-infective urinary catheters.
The contract runs 1 April 2017 to 31 March 2021 and covers both BIP Foley Catheter in latex and BIP Foley Catheter Silicone.
Bactiguard signs distribution agreement and enters partnership with Biodina for Brazil.
Brazil is the biggest market in Latin America and one of the most populous countries in the world with a population of over 200 million. Biodina is headquarted in Rio de Janeiro and has an extensive network of sales offices and sub-distributors covering all of Brazil.
Bactiguard has two revenue streams.
The BIP portfolio currently includes sales of the BIP Foley, BIP ETT and BIP CVC products.
License revenues are attributable to sales of products under license, which currently includes the Group's licensing agreement with C.R. Bard regarding Bactiguard coated Foley catheters for the USA, Japan, the UK, Ireland, Canada and Australia, a license agreement with Vigilenz Medical Devices for Bactiguard coated orthopaedic implants, covering the Asean region as well as a license agreement with Smartwise Sweden AB for Bactiguard-coated vascular injection catheters.
Comprises mainly foreign exchange differences and other operating income.
Bactiguard's BIP (Bactiguard Infection Protection) product portfolio includes medical devices in three areas: urinary tract, respiratory tract and blood streams.
Consolidated revenues for the first quarter amounted to SEK 41.0 (26.0) million, which is an increase of approx. 58 % compared to the same quarter last year. Excluding the revenue from new license agreement with Smartwise Sweden AB, the increase is 24 %. License revenue from C.R. Bard was on a normal level and thereby also higher than first quarter 2016.
The bulk of revenues during the first quarter (67 %) came from License revenues related to C.R. Bard and amounted to SEK 27.4 (22.8) million, including a positive currency effect of SEK 2.5 (-1.4) million. New license revenues from Smartwise Sweden AB was SEK 8.8 million (USD 1 million), or 21 % of revenues. This new license revenue represents the first part of a total revenue in 2017 of USD 2.5 million, for the exclusive and global right to the Bactiguard technology.
Sales of BIP products amounted to 7 % of revenues or approx. SEK 2.8 (2.9) million in the first quarter, with sales primarily to Europe and the Middle East. Out of SEK 2.8 million in revenues, SEK 2.5 million had a cash flow effect. The remaining revenues correspond to a reduction of the debt item deferred revenue in the balance sheet. Delivered volume is lower in the first quarter compared to the corresponding quarter previous year but is compensated by higher revenue per product following more sold products of higher value, i.e. central venous catheters (CVCs) and endotracheal tubes (ETTs).
Other revenues during the quarter amounted to 5 % or approx. SEK 2.0 (0.4) million and are attributable to exchange rate differences and EU grants for development projects.
| Jan-Mar | Jan-Mar | Full year | |
|---|---|---|---|
| Revenue split | 2017 | 2016 | 2016 |
| License revenues | 66,8% | 87,5% | 79,8% |
| New license revenues | 21,4% | 0,0% | 0,4% |
| Sales of BIP products | 6,9% | 11,1% | 12,3% |
| Other revenue | 4,9% | 1,4% | 7,5% |
During the first quarter of 2017 BIP products were delivered with a value of SEK 2.8 million (approx. 48,000 products) compared to approx. SEK 2.9 million (approx. 88,000 products) in the corresponding quarter of 2016.
During the full year 2016, a total of approx. 418,000 products were delivered with a value of SEK 15.8 million.
Development per quarter, value in TSEK for delivered BIP products, rolling 12 months.
1 Since the delivered product mix has changed over time, the importance of following only delivered volume has decreased in favour of illustrating the value of delivered BIP products.
EBITDA for the first quarter amounted to SEK 13.4 (-1.6) million corresponding to an EBITDA margin of approx. 33 % (neg). The positive change compared with the corresponding quarter last year is mainly a consequence of higher license revenues.
Consolidated operating profit for the first quarter of 2017 amounted to SEK 4.4 (-9.9) million.
Financial items for the quarter amounted to SEK -1.6 (-2.5) million. Interest expense related to interest bearing loans amounted to SEK -1.3 (-3.8) million in the first quarter.
Tax for the period amounted to SEK 1.4 (1.2) million and refers to the change in deferred taxes attributable to temporary differences relating to the Group's intangible assets.
Consolidated net profit for the first quarter amounted to SEK 4.1 (-11.2) million.
Operating cash flow (cash flow from operating activities after investments and changes in working capital) for the first quarter amounted to SEK -2.0 (1.8) million. Cash flow from operating activities contributed positively with SEK 11.7 (-2.7) million but Cash flow from changes in working capital contributed negatively with SEK -13.2 (6.5) million. Within working capital, the main part was the increase in accounts receivable related to the first partial invoice Smartwise Sweden AB. This receivable of USD 1 million was payed in April.
Cash flow from financing activities amounted to SEK 0.0 (0.0) million. Consequently, the total cash flow for the first quarter amounted to SEK -2.0 (1.8) million.
Investments in property, plant and equipment during the first quarter amounted to SEK 0.0 (0.6) million. Investments in intangible assets in the first quarter, mainly related to capitalised development expenditures, amounted to 0.5 (1.5) million. No investments were made in financial non-current assets during the quarter SEK (-) million.
The consolidated equity ratio was 61 % at 31 March 2017 (62 % at 31 December 2016) and equity amounted to SEK 394.4 million (SEK 390.3 million at 31 December 2016).
Interest bearing debt consists of a financial lease of SEK 15 million, a bank loan of SEK 100 million maturing 31 December, 2017 and a loan from the company's main shareholders of SEK 50 million, maturing 30 June 2018. The loans carry a base interest rate of STIBOR 90, but not less than 0 %, and a margin of 3.5 %. The financial lease liability has been accrued through an additional agreement to a previous operational lease commitment related to the production facility in Tullinge.
Consolidated cash position at 31 March 2017 amounted to SEK 13.7 million (SEK 15.6 million at 31 December 2016). Out of a granted overdraft facility of SEK 30 million, SEK 0 million was utilized as of 31 March, 2017. Net debt amounted to SEK 151.3 million (SEK 134.4 million at 31 December 2016).
The total assets of the Group at 31 March 2017 amounted to SEK 648.8 million (SEK 632.1 million at 31 December 2016). The largest asset item in the balance sheet is technology related to Bactiguard's product portfolio, which at 31 March 2017 amounted to SEK 230.7 million (SEK 236.6 million at 31 December 2016).
Accounts receivable (short- and long term) amounted to SEK 54.9 million at 31 March 2017, which is an increase of SEK 11.1 million since 31 December 2016. The main reason for the increase is the accounts receivable of USD 1 million related to the first part of the license deal with Smartwise Sweden AB. The receivable was payed after the end of the quarter, in April 2017.
Trade in the Bactiguard share takes place on Nasdaq Stockholm under the ticker symbol "BACTI". The last price paid for the listed B share at 31 March 2017 was SEK 17.00, and the market capitalization amounted to SEK 566 million.
The share capital of Bactiguard at 31 March 2017 amounted to SEK 0.8 million divided into 29,302,373 B shares, each with one vote (29,302,373 votes) and 4,000,000 A shares, each with ten votes (40,000,000 votes). The total number of shares and votes in Bactiguard at 31 March 2017 amounted to 33,302,373 shares and 69,302,373 votes.
| At 31 March 2017 Bactiguard had 2,493 shareholders. | |||||
|---|---|---|---|---|---|
| Shareholders | No. of A shares | No. of B shares | Total number | % of capital |
% of votes |
| CHRISTIAN KINCH WITH FAMILY AND COMPANY | 2 000 000 | 7 440 977 | 9 440 977 | 28,3% | 39,6% |
| THOMAS VON KOCH WITH COMPANY | 2 000 000 | 7 440 878 | 9 440 878 | 28,3% | 39,6% |
| HANDELSBANKEN FONDER AB | 1 214 260 | 1 214 260 | 3,6% | 1,8% | |
| AVANZA PENSION | 911 243 | 911 243 | 2,7% | 1,3% | |
| SWEDBANK FÖRSÄKRING | 707 913 | 707 913 | 2,1% | 1,0% | |
| STÅHLBERG, JAN | 582 544 | 582 544 | 1,7% | 0,8% | |
| CANCERFONDEN | 559 415 | 559 415 | 1,7% | 0,8% | |
| FRÖAFALL INVEST AB | 516 000 | 516 000 | 1,5% | 0,7% | |
| RUGFELT, JOHAN | 401 632 | 401 632 | 1,2% | 0,6% | |
| SARGAS EQUITY AB | 364 090 | 364 090 | 1,1% | 0,5% | |
| Total, major shareholders | 4 000 000 | 20 138 952 | 24 138 952 | 72,5% | 86,8% |
| Total, others | 0 | 9 163 421 | 9 163 421 | 27,5% | 13,2% |
| Total number of shares | 4 000 000 | 29 302 373 | 33 302 373 | 100% | 100% |
The average number of employees in the Group in the period January to March 2017 amounted to 64 (58), of which 38 (35) women.
The consolidated financial statements are prepared in accordance with International Financial Reporting Standards (IFRS). The interim report has been prepared in accordance with IAS 34 Interim Reporting and the Annual Accounts Act. Disclosures in accordance with IAS 34 Interim Reporting are submitted both in notes and elsewhere in the interim report. The parent company financial statements have been prepared in accordance with the Annual Accounts Act and the Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities.
The accounting and valuation principles are unchanged from those applied in the Annual Report 2016.
The new and amended standards and interpretations that are in place from 1 January, 2017 have not had any significant effect on the Group's financial reports.
An operating segment is a component of an entity that engages in business activities from which it may derive revenues and incur expenses, whose operating results are regularly reviewed by the chief operating decision maker and for which there is discrete financial information. The company's reporting of operating segments is consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker is the function that assesses the operating segment performance and decides how to allocate resources. The company has determined that the Group executive management constitutes the chief operating decision maker.
The company is considered in its entirety to operate within one business segment.
Transactions between the company and its subsidiaries, which are related parties to the company, have been eliminated on consolidation.
Services and other transactions between companies within the Group are charged according to commercial principles. Bactiguard has a bank loan of SEK 100 million where the board member - who is also the CEO and a major shareholder - Christian Kinch and major shareholder Thomas von Koch have agreed to, without compensation, enter into guarantee commitments for Bactiguard Holding AB's obligations under the loan agreement. Bactiguard has in addition also a loan directly from the main shareholders of SEK 50 million on equivalent commercial terms as the bank loan.
In the license agreement signed during the first quarter, the contracting party Smartwise Sweden AB is owned by a group of private investors, including Christian Kinch and Thomas von Koch.
Other than as described above, neither Bactiguard nor its subsidiaries have granted loans, guarantees or sureties to, or for the benefit of, any directors or senior managers of the Group. None of these persons has any direct or indirect participation in any other business transaction with any entity of the Group which is, or was, unusual in its nature or with regard to its terms.
Revenues consist of invoiced intercompany expenses (management fees). During the period the parent company received interest on its receivables from group companies. The company's financial expenses have decreased significantly compared with the corresponding quarter last year through the refinancing of the bond loan that occurred at the end of 2016. No investments were made during the period.
Companies within the Group are exposed to various types of risk through their activities. The company continually engages in a process of identifying all risks that may arise and assessing how each of these risks shall be managed. The Group is working to create an overall risk management programme that focuses on minimising potential adverse effects on the company's financial results. The company is primarily exposed to market related risks, operational risks and financial risks. A description of these risks can be found on page 27 and 45-46 in the Annual Report for 2016.
Bactiguard's goal is to create value and generate good returns for the shareholders. One financial target is to have an average growth of 20 % per year over a five year period, with 2015 (adjusted for the effect of the additional order from C.R. Bard) as the base year – starting point SEK 118.5 million in revenue. Another target is to achieve an EBITDA margin of at least 30 % at the end of the five year period. Bactiguard will continue to expand the business by strengthening the sales- and marketing organization, developing new products to the existing BIP portfolio and by entering new license agreements in new therapeutic areas. Other financial targets are to have an equity ratio of at least 30 % and a long-term objective of a dividend of 30-50 % of profit after tax, taking into consideration the company's financial position. The company is in an expansion phase and will therefore in the coming years, prioritize growth over dividends. Therefore, the Board has not proposed any dividend for the 2017 annual general meeting.
| Amounts in TSEK | Jan-Mar | Jan-Mar | Full year |
|---|---|---|---|
| 2017 | 2016 | 2016 | |
| Revenues | |||
| License revenues | 36 195 | 22 769 | 102 983 |
| Sales of BIP products | 2 834 | 2 886 | 15 753 |
| Other revenue | 1 998 | 352 | 9 606 |
| 41 027 | 26 008 | 128 342 | |
| Raw materials and consumables |
-3 870 | -2 583 | -15 797 |
| Other external expenses | -10 086 | -11 754 | -46 701 |
| Personnel costs | -12 707 | -11 613 | -45 819 |
| Depreciation and amortisation | -9 004 | -8 312 | -33 375 |
| Other operating expenses | -993 | -1 620 | -4 918 |
| -36 660 | -35 883 | -146 610 | |
| Operating profit/loss | 4 366 | -9 875 | -18 268 |
| Profit/loss from financial items | |||
| Financial income | 141 | 1 745 | 9 735 |
| Financial expenses | -1 781 | -4 250 | -22 800 |
| -1 641 | -2 505 | -13 065 | |
| Profit before tax | 2 725 | -12 380 | -31 333 |
| Taxes for the period | 1 356 | 1 166 | 4 482 |
| Net profit/loss for the period | 4 082 | -11 215 | -26 851 |
| Attributable to: | |||
| Shareholders of the parent | 4 082 | -11 215 | -26 851 |
| Amounts in TSEK | Jan-Mar 2017 |
Jan-Mar 2016 |
Full year 2016 |
|---|---|---|---|
| Net profit/loss for the period | 4 082 | -11 215 | -26 851 |
| Other comprehensive income: | |||
| Items that w ill be reclassified to profit or loss for the |
|||
| year | |||
| Translation differences | 34 | -461 | -264 |
| Other comprehensive income, after tax | 34 | -461 | -264 |
| Total comprehensive income for the period | 4 115 | -11 676 | -27 115 |
| Attributable to: | |||
| Shareholders of the parent | 4 115 | -11 676 | -27 115 |
| Total earnings per share, SEK* | 0,12 | -0,35 | -0,81 |
| Number of shares at the end of period ('000) | 33 302 | 33 302 | 33 302 |
| Weighted average number of shares ('000) | 33 302 | 33 302 | 33 302 |
* no dilution effect
| Amounts in TSEK | 2017-03-31 | 2016-03-31 | 2016-12-31 |
|---|---|---|---|
| ASSETS | |||
| Non-current assets | |||
| Goodw ill |
226 292 | 226 292 | 226 292 |
| Technology | 230 660 | 254 467 | 236 612 |
| Brands | 25 572 | 25 572 | 25 572 |
| Customer relationships | 11 433 | 12 613 | 11 728 |
| Capitalised development expenditure | 16 608 | 13 040 | 16 562 |
| Patents | 883 | 1 218 | 1 021 |
| Intangible assets | 511 448 | 533 202 | 517 787 |
| Improvements, leasehold | 15 357 | 17 848 | 16 133 |
| Machinery and other technical plant | 19 951 | 7 151 | 5 659 |
| Equipment, tools and installations | 3 550 | 5 129 | 3 937 |
| Property, plant and equipment | 38 858 | 30 127 | 25 728 |
| Accounts receivable | 16 256 | 6 012 | 16 170 |
| Investments in associates | 1 228 | 1 298 | 1 228 |
| Financial assets | 17 484 | 7 310 | 17 398 |
| Total non-current assets | 567 790 | 570 640 | 560 912 |
| Current assets | |||
| Inventory | 15 497 | 12 394 | 15 144 |
| Accounts receivable | 38 628 | 46 744 | 27 642 |
| Other current receivables | 13 198 | 13 586 | 12 732 |
| Cash and cash equivalents | 13 682 | 24 094 | 15 645 |
| Total current assets | 81 005 | 96 818 | 71 162 |
| TOTAL ASSETS | 648 795 | 667 457 | 632 074 |
| Equity attributable to shareholders of the parent | |||
| Share capital | 833 | 833 | 833 |
| Other equity | 393 611 | 404 934 | 389 496 |
| Total equity | 394 444 | 405 767 | 390 328 |
| Non-current liabilities | |||
| Advance payments from customers | 18 306 | - | 18 207 |
| Debt to Shareholders | 50 000 | - | 50 000 |
| Deferred tax liability | 28 929 | 33 602 | 30 285 |
| Other long-term liabilities | 13 925 | - | - |
| 111 159 | 33 602 | 98 492 | |
| Current liabilities | |||
| Liabilities to credit institutions | 100 000 | - | 100 000 |
| Bond loan | - | 141 450 | - |
| Accounts payable | 4 653 | 4 588 | 4 896 |
| Other current liabilities | 5 097 | 4 182 | 3 835 |
| Accrued expenses and deferred income | 33 441 | 77 868 | 34 523 |
| 143 192 | 228 088 | 143 254 | |
| Total liabilities | 254 351 | 261 690 | 241 746 |
| TOTAL EQUITY AND LIABILITIES | 648 795 | 667 457 | 632 074 |
| Amounts in TSEK | Equity attributable to shareholders of the parent | ||||
|---|---|---|---|---|---|
| Share capital | Other capital contributions |
Translation reserve |
Retained earnings including net profit for the period |
Total equity | |
| Adjusted opening balance, 1 January 2016 Profit/loss for the period |
833 - |
675 690 - |
352 - |
-259 432 -11 215 |
417 443 -11 215 |
| Other comprehensive income: Translation differences |
- | - | -461 | - | -461 |
| Total comprehensive income after tax | 0 | 0 | -461 | -11 215 | -11 676 |
| Transactions with shareholders | |||||
| Total transactions with shareholders | 0 | 0 | 0 | 0 | 0 |
| Closing balance, 31 March 2016 | 833 | 675 690 | -109 | -270 647 | 405 767 |
| Opening balance, 1 January 2017 Profit/loss for the period |
833 - |
675 690 - |
88 - |
-286 283 4 082 |
390 328 4 082 |
| Other comprehensive income: Translation differences |
- | - | 34 | - | 34 |
| Total comprehensive income after tax | 0 | 0 | 34 | 4 082 | 4 115 |
| Transactions with shareholders | |||||
| Total transactions with shareholders | 0 | 0 | 0 | 0 | 0 |
| Closing balance, 31 March 2017 | 833 | 675 690 | 122 | -282 201 | 394 444 |
| Amounts in TSEK | Jan-Mar | Jan-Mar | Full year |
|---|---|---|---|
| 2017 | 2016 | 2016 | |
| Cash flow from operating activities | |||
| Net profit/loss for the period | 4 082 | -11 215 | -26 851 |
| Adjustments for depreciation and amortisation and other | |||
| non-cash items | 7 593 | 8 556 | 22 967 |
| 11 674 | -2 659 | -3 884 | |
| Cash flow from changes in working capital | |||
| Increase/decrease inventory | -359 | -660 | -3 416 |
| Increase/decrease accounts receivable | -10 931 | 4 528 | -803 |
| Increase/decrease other current receivables | -435 | 1 697 | 370 |
| Increase/decrease accounts payable | -241 | 285 | 933 |
| Increase/decrease other current liabilities | -1 190 | 646 | -5 611 |
| -13 157 | 6 496 | -8 527 | |
| Cash flow from investing activities1) | |||
| Investments in intangible assets | -459 | -1 468 | -6 450 |
| Investments in property, plant and equipment | -14 | -605 | -961 |
| -474 | -2 073 | -7 411 | |
| Operating cash flow | -1 956 | 1 764 | -19 822 |
| Cash flow from financing activities1) | |||
| Amortisation of loan | - | - | -138 000 |
| Debt incurred | - | - | 150 000 |
| 0 | 0 | 12 000 | |
| Cash flow for the period | -1 956 | 1 764 | -7 822 |
| Cash and cash equivalents at start of period | 15 645 | 22 119 | 22 119 |
| Exchange difference in cash and cash equivalents | -7 | 211 | 1 348 |
| Cash and cash equivalents at end of period | 13 682 | 24 094 | 15 645 |
1) Financial lease is net reported in cash flow
| Amounts in TSEK | Jan-Mar 2017 |
Jan-Mar 2016 |
Full year 2016 |
Full year 2015 |
|---|---|---|---|---|
| Revenues | 1 632 | 2 154 | 7 563 | 7 036 |
| 1 632 | 2 154 | 7 563 | 7 036 | |
| Operating expenses | -2 532 | -2 523 | -10 328 | -15 502 |
| -2 532 | -2 523 | -10 328 | -15 502 | |
| Operating profit/loss | -900 | -369 | -2 765 | -8 466 |
| Net financial items | -588 | -6 120 | -26 897 | -22 399 |
| Profit/loss after financial items | -1 488 | -6 489 | -29 662 | -30 865 |
| Tax for the period | - | - | - | |
| Net profit/loss for the period | -1 488 | -6 489 | -29 662 | -30 865 |
The parent company has no items in 2017 or 2016 recognised in other comprehensive income. Net profit/loss for the period for the parent company thereby also constitutes the comprehensive income for the period. The parent company therefore presents no separate statement of comprehensive income.
| Amounts in TSEK | 2017-03-31 | 2016-03-31 | 2016-12-31 |
|---|---|---|---|
| ASSETS | |||
| Non-current assets | |||
| Financial assets | 598 089 | 699 774 | 598 089 |
| Total non-current assets | 598 089 | 699 774 | 598 089 |
| Current assets | |||
| Receivables from group companies | 19 890 | 16 451 | 22 395 |
| Prepayments and accrued income | 430 | 1 264 | 243 |
| Cash and cash equivalents | 1 594 | 11 022 | 1 118 |
| Total current assets | 21 913 | 29 111 | 23 756 |
| TOTAL ASSETS | 620 002 | 728 885 | 621 845 |
| EQUITY & LIABILITIES | |||
| Total equity | 467 043 | 491 705 | 468 531 |
| Non-current liabilities | 50 000 | - | 50 000 |
| Liabilities to credit institutions | 100 000 | - | 100 000 |
| Bond loan | - | 225 843 | - |
| Other liabilities | 2 960 | 11 337 | 3 314 |
| Current liabilities | 102 960 | 237 180 | 103 314 |
| Total liabilities | 152 960 | 237 180 | 153 314 |
| TOTAL EQUITY AND LIABILITIES | 620 002 | 728 885 | 621 845 |
Equity and untaxed reserves (less deferred tax) in relation to the balance sheet total
Interest-bearing liabilities less cash and cash equivalents
Earnings before interest, taxes, depreciation and amortisation
EBITDA margin EBITDA/revenue
Earnings for the period/weighted average number of shares during the period, issue-adjusted
Cash flow from operating activities after investments and changes in working capital
Financial income minus financial expenses
The Company presents certain financial measures in the interim report that are not defined under IFRS. The Company believes that these measures provide useful supplemental information to investors and the company's management as they allow for the evaluation of the company's performance. Because not all companies calculate the financial measures in the same way, these are not always comparable to measures used by other companies. Therefore, these financial measures should not be considered as substitutes for measures as defined under IFRS.
The tables below present measures that are not defined under IFRS.
Show s the companys earning pow er from ongoing operations irrespective of capital structure and tax situation and is meant to facilitate comparisons w ith other companies in the same industry.
| Amounts in TSEK | Jan-Mar | Jan-Mar | Full year | |
|---|---|---|---|---|
| 2017 | 2016 | 2016 | ||
| Operating profit/loss | 4 366 | -9 875 | -18 268 | |
| Depreciation and amortisation | 9 004 | 8 312 | 33 375 | |
| EBITDA | 13 370 | -1 563 | 15 107 | |
Net debt
Is a measurement used to describe the group's indebtedness and its ability to repay its debt w ith cash generated from the group's operating activities if the debts matured today.
| Amounts in TSEK | Jan-Mar | Jan-Mar | Full year | |
|---|---|---|---|---|
| 2017 | 2016 | 2016 | ||
| Interest-bearing liabilities | 164 996 | 141 450 | 150 000 | |
| Cash and cash equivalents | -13 682 | -24 094 | -15 645 | |
| Net debt | 151 315 | 117 356 | 134 355 | |
| 10 August 2017 | Interim report, 1 Apr – 30 Jun 2017 |
|---|---|
| 9 November 2017 | Interim report, 1 Jul – 30 Sep 2017 |
The Annual General Meeting of Bactiguard Holding AB (publ) will be held on Thursday, 18 May 2017 in Botkyrka.
For additional information, please contact:
Christian Kinch, CEO: +46 8 440 58 80
Fredrik Järrsten, CFO: +46 725 500 089
The Board of Directors and the CEO certify that the interim report, to the best of their knowledge, provides a fair overview of the parent company's and the group's operations, financial position and results and describes the material risks and uncertainties faced by the parent company and the companies included in the Group.
Stockholm, 4 May 2017
| Stanley Brodén | Mia Arnhult |
|---|---|
| Chairman | Board member |
| Peter Hentschel | Marie Wickman-Chantereau |
| Board member | Board member |
Christian Kinch
CEO and Board member
Bactiguard is a Swedish medtech company with a mission to save lives. To achieve this mission, we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard coating prevents healthcare associated infections through reducing bacterial adhesion and formation on medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan through our license partner C.R. Bard and the company has also its own product portfolio consisting of urinary catheters, endotracheal tubes and central venous catheters. Bactiguard is in a strong expansion phase focused on the European markets, Middle East, Asia and Latin America. The company has about 60 employees worldwide. Its headquarters and production facility is in Stockholm. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com.
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above 2017-05-04, at. 08.00
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.